Efficacy News and Research

RSS

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

20 Oct 2010

EPO grants new patent to Silence Therapeutics’ RNAi structural modification technology

Silence Therapeutics plc announces that the European Patent Office (EPO) has granted a new patent that provides broad protection on novel aspects of the RNAi structural modification technology known as the Zamore Design Rules.

20 Oct 2010

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.

20 Oct 2010

Study finds different activity patterns of genes in brain of individuals with different genetic backgrounds

Researchers at the Allen Institute for Brain Science have found that the same genes have different activity patterns in the brain in individuals with different genetic backgrounds. These findings may help to explain individual differences in the effectiveness and side-effect profiles of therapeutic drugs and thus have implications for personalized medicine. The study is available in this week's online early edition of the Proceedings of the National Academy of Sciences (www.pnas.org).

20 Oct 2010

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new contracts for large-scale clinical trials that address the problem of antimicrobial resistance.

20 Oct 2010

Experts at Ninth International Symposium discuss health effects and safety of S-equol

The latest research into the health effects and safety of a soy-based compound called S-equol was described in talks and presentations by experts at a special session on Tuesday, Oct. 19 during the Ninth International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment, held Oct. 16 to 19 in Washington, D.C.

20 Oct 2010

NCI awards 20/20 GeneSystems $3 million to develop tests for targeted cancer therapies

20/20 GeneSystems, Inc. announced today at the AdvaMed MedTech Conference in Washington, D.C. that the company has been awarded nearly $3 million in grants from the National Cancer Institute's (NCI) Small Business Innovative Research (SBIR) Program to develop tests to help oncologists predict the effectiveness of targeted cancer therapies.

20 Oct 2010

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

The U.S. Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).

20 Oct 2010

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Adamis Pharmaceuticals Corporation today announced the completion of the acquisition from Colby Pharmaceuticals of the remaining exclusive license agreements relating to two drug product candidates for the treatment of prostate cancer (PCa).

20 Oct 2010

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

20 Oct 2010

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

20 Oct 2010

Coal seam gas toxins raise questions

Routine testing by Australia Pacific LNG found traces of four toxic chemicals, including benzene and toluene, in their wells in the Surat Basin. There are fresh calls for a ban on the extraction of coal seam gas in southern Queensland.

19 Oct 2010

Xenogenics acquires Ideal BioStent assets

MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.

19 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

TearLab announces publication of CPT code for Osmolarity test

TearLab Corporation announced today that, further to its press release of October 8, 2010, a unique new Current Procedural Terminology code that will apply to the TearLab Osmolarity test has now been published by the American Medical Association. The new code will become effective January 1, 2011.

19 Oct 2010

Arcadia Biosciences receives Canadian marketing clearance for SONOVA 400 health product

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, today announced that Health Canada has granted the company clearance to sell SONOVA 400 in Canada. With the December 2009 completion of the New Dietary Ingredient (NDI) regulatory process in the United States, Arcadia is now able to make the health-maintaining oil available throughout the US and Canada.

19 Oct 2010

Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC

Adolor Corporation today announced the initiation of a Phase 2 proof-of-concept (PoC) study of ADL5945 in patients suffering from opioid-induced constipation (OIC).

19 Oct 2010

60 Plus applauds FDA decision to remove unapproved colchicine products

James L. Martin, chairman of the 60 Plus Association, a seniors advocacy group, applauded the Food and Drug Administration's (FDA) decision to remove unapproved colchicine products from the market, and called on drug manufacturers, distributors and pharmacies to help the FDA protect patients from unapproved drugs.

19 Oct 2010

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis.The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

19 Oct 2010

Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis

Estimates of the prevalence of liver disease suggest that one‐third of the United States population has non‐alcoholic fatty liver disease (NAFLD). NAFLD is now the most common cause for elevated liver function tests in the United States, a trend related to the obesity epidemic in this country. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis and all its complications.

19 Oct 2010

Efficacy News and Research

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

EPO grants new patent to Silence Therapeutics’ RNAi structural modification technology

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

Study finds different activity patterns of genes in brain of individuals with different genetic backgrounds

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

Experts at Ninth International Symposium discuss health effects and safety of S-equol

NCI awards 20/20 GeneSystems $3 million to develop tests for targeted cancer therapies

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

Coal seam gas toxins raise questions

Xenogenics acquires Ideal BioStent assets

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

TearLab announces publication of CPT code for Osmolarity test

Arcadia Biosciences receives Canadian marketing clearance for SONOVA 400 health product

Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC

60 Plus applauds FDA decision to remove unapproved colchicine products

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News